MDGL — Madrigal Pharmaceuticals, Inc.

Summary of Madrigal Pharmaceuticals Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Net Sales: $321.1 million, more than tripling from Q4 2024.
• Full Year 2025 Net Sales: $958.4 million, marking a strong launch for Rezdiffra.
• Gross-to-Net Impact: Increased from Q3 to Q4 2025, with an average for the year at the low end of the 20%-30% range.
• Cash Position: Ended Q4 2025 with $988.6 million in cash, cash equivalents, and marketable securities.
• R&D Expenses: $116.3 million for Q4 and $388.5 million for the full year, driven by business development activities.
• SG&A Expenses: $240 million for Q4 and $813.8 million for the full year, reflecting support for Rezdiffra's launch.

2. Strategic Updates and Business Highlights

• Rezdiffra Launch: Established as the foundational therapy in the MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) market, with nearly $1 billion in net sales in its first year.
• Market Growth: The U.S. MASH market has grown nearly 50% since 2023, with expectations for continued double-digit growth.
• Pipeline Expansion: Added more than 10 programs, including an oral GLP-1, a late-stage DGAT-2 inhibitor, and six preclinical siRNA targets, aimed at combination therapies with Rezdiffra.
• International Rollout: Initiated the ex-U.S. rollout starting in Germany, although contributions from this market are expected to be negligible in 2026.

3. Forward Guidance and Outlook

• 2026 Expectations: Anticipate robust net sales growth despite a step-up in gross-to-net from contracting, with projections for a high 30% gross-to-net impact.
• Patient Growth: Expect to continue adding patients steadily, with a target of approximately 6,000 to 7,000 new patients per quarter.
• Long-term Potential: The F4c population (compensated MASH cirrhosis) could double Rezdiffra's market opportunity, with plans to submit for regulatory approval.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The launch of GLP-1 therapies like Wegovy has introduced competition, but management believes Rezdiffra's profile remains strong.
• International Market Uncertainty: The rollout in Germany and other ex-U.S. markets is uncertain, with negligible contributions expected in 2026.
• Gross-to-Net Dynamics: The transition to a higher gross-to-net impact due to new payer contracts may impact revenue growth in the short term.

5. Notable Q&A Insights

• Patient Diagnosis and Growth: Increased awareness and competition are driving more diagnoses and patient starts, with no significant shift in the types of patients prescribed Rezdiffra.
• Reimbursement Challenges: Reauthorizations for long-term patients are routine, with physician attestation often required, but management believes the chronic nature of MASH will support ongoing treatment.
• Combination Therapy Strategy: The company is focused on advancing combination therapies while ensuring that only promising programs are pursued, emphasizing adaptability in their pipeline strategy.
• AI in Clinical Trials: The FDA's approval of AI-supported pathology reads may influence future studies, particularly for biopsy-driven trials, but current studies are primarily event-driven.

This summary encapsulates the key aspects of Madrigal Pharmaceuticals' Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced.